Related Experiment Videos
HPC2 variants and screen-detected prostate cancer
D Vesprini1, R K Nam, J Trachtenberg
1Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada.
American Journal of Human Genetics
|March 20, 2001
Summary
Genetic variants in the HPC2/ELAC2 gene are not useful for predicting prostate cancer. Genotyping these polymorphisms showed no significant difference in prevalence among men with prostate cancer, other prostate conditions, or healthy women.
Area of Science:
- Genetics
- Oncology
- Urology
Background:
- Previous studies suggested associations between HPC2/ELAC2 gene variants and prostate cancer susceptibility.
- The relative risks for these variants were estimated to be two- to threefold.
Purpose of the Study:
- To investigate the utility of HPC2/ELAC2 gene polymorphisms in predicting prostate cancer presence.
- To evaluate these variants as potential predictors in men with elevated PSA levels undergoing biopsy.
Main Methods:
- Genotyping of 944 men undergoing prostate biopsy and 922 healthy women as controls.
- Analysis of the prevalence of the HPC2 Ala541Thr allele in different study groups.
Main Results:
- The prevalence of the HPC2 Ala541Thr allele was similar across all groups: men with prostate cancer (6.3%), men with other prostatic conditions (6.8%), and healthy women (6.3%).
- Statistical analysis showed no significant difference (P = .83).
Conclusions:
- HPC2 genotyping is unlikely to be a valuable addition to PSA testing for predicting biopsy-detected prostate cancer.
- These findings suggest that HPC2/ELAC2 variants do not aid in the clinical prediction of prostate cancer in asymptomatic men with elevated PSA.